Rare Daily Staff

Attralus reported that it has closed a $116 million series B financing to advance a pipeline focused on improving the lives of patients with systemic amyloidosis.

Logos Capital led the financing round, which included participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), Vivo Capital, and founding investor, VenBio Partners.

“This financing from a world-class syndicate of investors with deep expertise and experience in the life science space reflects the recognition of the strong potential of our pipeline of innovative pan-amyloid removal (PAR) therapeutics to bring a new treatment approach to patients with systemic amyloidosis,” said Mark Timney, CEO of Attralus. “With this support, we will accelerate our strategy to advance our PAR therapeutic programs into clinical trials along with the world’s first amyloidosis-specific diagnostic imaging agent.”

Systemic amyloidosis encompasses a diverse group of rare diseases that occur due to accumulation of toxic amyloid deposits in tissues and organs, a consequence of aberrant protein misfolding events. These diseases are progressive, debilitating and often fatal. Systemic amyloidosis is significantly underdiagnosed due to low awareness, lack of specific symptoms, and no current disease-specific diagnostics. The two most common forms of systemic amyloidosis are immunoglobulin light-chain (AL) amyloidosis and transthyretin amyloidosis (ATTR).

Attralus’ proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

Proceeds from the financing will be used to prepare the advancement of Attralus’ PAR therapeutics into clinical trials. The first PAR therapeutic, AT-03, is expected to begin a phase 1 biodistribution study in systemic amyloidosis patients. AT-03 is a fusion of the company’s PAR-SAP (Serum Amyloid Protein) technology with a single-chain Fc. The PAR-SAP component mediates binding to all types of amyloid deposits, and the single-chain Fc stimulates the immune system to remove amyloid deposits that are bound by AT-03.

Additionally, the company plans to advance the AT-01 clinical program, an amyloid-specific imaging radiotracer for the diagnosis of systemic amyloidosis. AT-01 utilizes the company’s pan-amyloid peptide, an amyloid specific radiotracer to image all types of systemic amyloidosis through PET/CT imaging. In initial clinical trials, AT-01 has been shown to detect all types of amyloid deposits, including AL and ATTR, in major organs such as the heart, kidney, liver and spleen.

The funding will also enable the company to expand its team and infrastructure to support future growth.

“Attralus offers unique value by developing amyloidosis therapies capable of broadly removing existing amyloid deposits, going beyond current treatments that slow progression but do not remove amyloid from organs,” said Graham Walmsley and Arsani William, both partners at Logos Capital.

Photo: Mark Timney, CEO of Attralus

X